SFM
RARE icon

Sphera Funds Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sphera Funds Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6M Sell
588,494
-220,839
-27% -$5.49M 2.56% 8
2026
Q1 		$17M Buy
809,333
+508,710
+169% +$11.5M 2.69% 9
2025
Q4 		$6.91M Sell
300,623
-51,935
-15% -$1.71M 1.34% 25
2025
Q3 		$10.6M Buy
352,558
+252,473
+252% +$7.57M 2.24% 8
2025
Q2 		$3.64M Sell
100,085
-167,300
-63% -$6.03M 0.85% 43
2025
Q1 		$9.68M Buy
267,385
+38,609
+17% +$1.61M 2.23% 9
2024
Q4 		$9.62M Buy
228,776
+33,427
+17% +$1.66M 1.74% 14
2024
Q3 		$10.9M Sell
195,349
-98,483
-34% -$5.02M 1.73% 17
2024
Q2 		$12.1M Buy
293,832
+55,288
+23% +$2.36M 1.65% 16
2024
Q1 		$11.1M Buy
238,544
+37,500
+19% +$1.77M 1.56% 20
2023
Q4 		$9.61M Sell
201,044
-58,091
-22% -$2.25M 1.55% 21
2023
Q3 		$9.24M Buy
259,135
+75,439
+41% +$2.99M 1.68% 13
2023
Q2 		$8.47M Hold
183,696
– – 1.32% 18
2023
Q1 		$7.37M Hold
183,696
– – 1.23% 26
2022
Q4 		$8.51M Buy
183,696
+10,000
+6% +$393K 1.83% 15
2022
Q3 		$7.19M Buy
+173,696
New +$8.93M 1% 30
2020
Q1 		– Sell
-115,000
Closed -$4.91M – 94
2019
Q4 		$4.91M Buy
+115,000
New +$4.74M 0.4% 55
2016
Q3 		– Sell
-105,000
Closed -$5.14M – 117
2016
Q2 		$5.14M Buy
+105,000
New +$6.79M 1.33% 17
2015
Q4 		– Sell
-30,700
Closed -$2.96M – 132
2015
Q3 		$2.96M Sell
30,700
-17,000
-36% -$1.95M 0.38% 62
2015
Q2 		$4.88M Buy
+47,700
New +$3.7M 0.48% 47

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Sphera Funds Management's RARE Position: Q2 2026 in Review

Sphera Funds Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 27% in Q2 2026, selling an estimated $5.49M and leaving 588,494 shares worth $19.6M. The position accounts for 2.56% of the portfolio, ranked #8.

Sphera Funds Management first reported a position in RARE in Q2 2015 and has held it in 20 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Sphera Funds Management held 588,494 shares of Ultragenyx Pharmaceutical worth $19.6M as of Q2 2026.
  • Sphera Funds Management sold 220,839 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $5.49M.
  • Ultragenyx Pharmaceutical made up 2.56% of Sphera Funds Management's portfolio in Q2 2026, its #8 holding.
  • Sphera Funds Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 20 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.